Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Total Valuation
TriSalus Life Sciences has a market cap or net worth of $211.14M. The enterprise value is $289.52M.
Market Cap$211.14M
Enterprise Value$289.52M
Share Statistics
TriSalus Life Sciences has 37,838,963 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding37,838,963
Owned by Insiders42.62%
Owned by Institutions5.14%
Financial Efficiency
TriSalus Life Sciences’s return on equity (ROE) is 1.28 and return on invested capital (ROIC) is -259.13%.
Return on Equity (ROE)1.28
Return on Assets (ROA)-1.39
Return on Invested Capital (ROIC)-259.13%
Return on Capital Employed (ROCE)-2.63
Revenue Per Employee267.55K
Profits Per Employee-273.14K
Employee Count110
Asset Turnover1.23
Inventory Turnover1.01
Valuation Ratios
The current PE Ratio of TriSalus Life Sciences is -4.00. TriSalus Life Sciences’s PEG ratio is -0.09.
PE Ratio-4.00
PS Ratio0.00
PB Ratio-1.68
Price to Fair Value-5.13
Price to FCF-8.97
Price to Operating Cash Flow-9.19
PEG Ratio-0.09
Income Statement
In the last 12 months, TriSalus Life Sciences had revenue of 29.43M and earned -33.23M in profits. Earnings per share was -1.25.
Revenue29.43M
Gross Profit25.33M
Operating Income-36.16M
Pretax Income-30.04M
Net Income-33.23M
EBITDA-36.16M
Earnings Per Share (EPS)-1.25
Cash Flow
In the last 12 months, operating cash flow was -34.48M and capital expenditures -1.03M, giving a free cash flow of -35.51M billion.
Operating Cash Flow-34.48M
Free Cash Flow-35.51M
Free Cash Flow per Share-0.94
Dividends & Yields
TriSalus Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.79
52-Week Price Change-5.66%
50-Day Moving Average5.37
200-Day Moving Average4.92
Relative Strength Index (RSI)54.14
Average Volume (3m)39.44K
Important Dates
TriSalus Life Sciences upcoming earnings date is Aug 14, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 14, 2025
Ex-Dividend Date―
Financial Position
TriSalus Life Sciences as a current ratio of 2.02, with Debt / Equity ratio of -1.11%
Current Ratio2.02
Quick Ratio1.63
Debt to Market Cap0.17
Net Debt to EBITDA-0.42
Interest Coverage Ratio-11.70
Taxes
In the past 12 months, TriSalus Life Sciences has paid 6.00K in taxes.
Income Tax6.00K
Effective Tax Rate>-0.01
Enterprise Valuation
TriSalus Life Sciences EV to EBITDA ratio is -4.09, with an EV/FCF ratio of -3.59.
EV to Sales5.02
EV to EBITDA-4.09
EV to Free Cash Flow-3.59
EV to Operating Cash Flow-3.62
Balance Sheet
TriSalus Life Sciences has $13.00M in cash and marketable securities with $33.12M in debt, giving a net cash position of $20.12M billion.
Cash & Marketable Securities$13.00M
Total Debt$33.12M
Net Cash$20.12M
Net Cash Per Share$0.53
Tangible Book Value Per Share-$0.98
Margins
Gross margin is 81.79%, with operating margin of -122.88%, and net profit margin of -112.92%.
Gross Margin81.79%
Operating Margin-122.88%
Pretax Margin-102.07%
Net Profit Margin-112.92%
EBITDA Margin-122.88%
EBIT Margin-112.56%
Analyst Forecast
The average price target for TriSalus Life Sciences is $11.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.50
Price Target Upside119.05% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast85.03%
EPS Growth Forecast53.73%